Niva Bupa Health Insurance Company Limited (NIVABUPA) Q1 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch
Niva Bupa Health Insurance enters Q1 FY27 with strong momentum, having achieved a 10.1% retail health market share by the end of FY26. Investors will be closely watching the impact of the new Ind AS accounting transition on reported margins and whether the company can sustain its sub-100% Combined Insurance Service Ratio (CISR) in a typically high-acquisition quarter.
| Results date | July 30, 2026 |
|---|---|
| Quarter | Q1 FY 2026-2027 |
| Previous quarter revenue | Rs. 3,123.4 Cr |
| Previous quarter PAT | Rs. 157.8 Cr |
| Previous quarter EBITDA margin | 97.4% |
| Market cap | Rs. 16,021.76 Cr |
| CMP | Rs. 86.64 |
Niva Bupa Health Insurance Company Limited Q1 Results Date and Time
The board meeting is scheduled for July 30, 2026, to consider the Q1 FY27 financial results.
What to expect from Niva Bupa Health Insurance Company Limited's Q1 FY27 results
Niva Bupa enters the new fiscal year following a strong FY26 performance where retail health GWP grew 35.0% to Rs. 6,581.5 Cr. The company's strategy to offset medical inflation through annual single-digit price increases remains a core focus, especially as the IFRS claims ratio rose to 64.9% in FY26. Management has maintained a long-term retail industry growth outlook of 17%–19% CAGR, which provides a structural tailwind for the firm's expansion.
The transition to Ind AS accounting starting this quarter is expected to improve transparency, though it may introduce volatility compared to previous IFRS reporting. The upcoming call will likely focus on the sustainability of the sub-100% CISR achieved in Q4 FY26 and the status of regulatory forbearance for prior-year expense limits.
Key Things To Watch
Performance vs Guidance Tracking: Tracking progress against long-term strategic targets.
- GWP scale target of Rs. 15,000–16,000 Cr by FY28–FY29
- Combined ratio target of ~99% by FY29
- ROE target of mid-to-high teens by FY29
Operating metric trajectory: Tracking the efficiency of the retail health business.
- Sustainability of sub-100% CISR (Q4 FY26 was 97.4%)
- Retail health loss ratio trajectory relative to the FY26 level of 66.8%
- SME group health growth pace, targeting ~50% growth
Strategic execution and regulatory updates: Key governance and operational milestones.
- IFRS 17 / Ind AS transition impact on earnings comparability
- Status of IRDAI approval for FY25 EOM forbearance
- Cashless SLA recovery post-resolution of auto-adjudication issues
Ask about this
Ask Cofacto a question about this company. Answers cite filings and company data.
Frequently Asked Questions
What was Niva Bupa's retail health market share at the end of FY26?
Niva Bupa's retail health market share reached 10.1% at the end of FY26, up from 9.4% in FY25. This growth was supported by a 35.0% YoY increase in retail health GWP.
What is the status of the company's Combined Insurance Service Ratio (CISR)?
The CISR improved by 160 bps in FY26 to 101.4%, with the company achieving a sub-100% ratio of 97.4% for the first time in Q4 FY26. Management is focused on sustaining this profitability level while managing acquisition costs.
Related
- Niva Bupa Health Insurance Company Ltd (NIVABUPA) Q1 FY27 Results Analysis: PAT Nearly Doubles, Combined Ratio Improves 495 bpsQ1 FY2026-2027 Results Analysis
- Niva Bupa Health Insurance Company Ltd (NIVABUPA) Q1 FY27 Earnings Call: Guides 8-10 ppt Retail Health Outperformance, CISR Improves 300 bps to 100.2%Q1 FY2026-2027 Earnings Call